TNFRSF8 and Hodgkins lymphoma: HL cells highly express CD30; therefore, it was considered an ultimate target by engineered CAR-T cells, and clinical trials showed encouraging results where patients diagnosed with HL exhibited complete remission after anti-CD30 CAR-T cell therapy, wherein other patients either developed stable disease or relapse; however, the observations of anti-CD30 CAR-T cells did not show any toxicities or adverse events (Ramos et al., 2017; Wang et al., 2017).